Methods of Generation of Induced Pluripotent Stem Cells and Their Application for the Therapy of Central Nervous System Diseases

Cherkashova, Elvira; Leonov, Georgy; Namestnikova, Daria; Соловьева, А. А.; Gubskii, I L; Бухарова, Т. Б.; Губский, Л.В.; Goldstein, D V; Yarygin, K N

doi:10.1007/s10517-020-04754-4

Cited by 6 publications

(5 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first iPSCs were generated through virus-mediated (mainly lentiviruses and retroviruses) transduction of transcription factors, leading to direct integration within the host cell genome, which remains the gold standard of iPSC generation today. However, methods that circumvent genome modification, also called non-integrating techniques, are being extensively developed and evaluated [ 27 , 28 , 29 ]. Indeed, the dominant trends in reprogramming technology are designed to prevent insertional mutagenesis (by using non-integrative approaches) and contamination of donor cells with co-cultured feeder cells (by using xeno-free conditions and defined extracellular matrix components).…”

Section: Ipsc Generation and Cardiac Differentiationmentioning

confidence: 99%

iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams

2021

View full text Add to dashboard Cite

Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of laboratory-induced pluripotent stem cells (iPSCs) that harbor the capability to become any cell type. Like other experimental strategies, stem cell therapy must meet multiple requirements before reaching the clinical trial phase, and in vivo models are indispensable for ensuring the safety of such novel therapies. Specifically, translational studies in large animal models are necessary to fully evaluate the therapeutic potential of this approach; to empirically determine the optimal combination of cell types, supplementary factors, and delivery methods to maximize efficacy; and to stringently assess safety. In the present review, we summarize the main strategies employed to generate iPSCs and differentiate them into cardiomyocytes in large animal species; the most critical differences between using small versus large animal models for cardiovascular studies; and the strategies that have been pursued regarding implanted cells’ stage of differentiation, origin, and technical application.

show abstract

Section: Ipsc Generation and Cardiac Differentiationmentioning

confidence: 99%

iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams

2021

View full text Add to dashboard Cite

show abstract

“…iPSCs are classically generated by the integration of transcription factors with a viral vector, which may cause tumorigenesis and/or unpredictable mutagenesis in the genome. hiPSCs generated by non-integration methods, such as mRNA [ 36 ], plasmid [ 37 ], small molecules [ 38 ], are safer candidates for transplantation, although they are normally with comparatively low reprogramming efficiency [ 39 ].…”

Section: Different Cell Types and The Current Progressmentioning

confidence: 99%

Cell Therapy for Neurological Disorders: The Perspective of Promising Cells

Liu

Bobrovskaya

Zhou

2021

Biology

View full text Add to dashboard Cite

Neurological disorders are big public health challenges that are afflicting hundreds of millions of people around the world. Although many conventional pharmacological therapies have been tested in patients, their therapeutic efficacies to alleviate their symptoms and slow down the course of the diseases are usually limited. Cell therapy has attracted the interest of many researchers in the last several decades and has brought new hope for treating neurological disorders. Moreover, numerous studies have shown promising results. However, none of the studies has led to a promising therapy for patients with neurological disorders, despite the ongoing and completed clinical trials. There are many factors that may affect the outcome of cell therapy for neurological disorders due to the complexity of the nervous system, especially cell types for transplantation and the specific disease for treatment. This paper provides a review of the various cell types from humans that may be clinically used for neurological disorders, based on their characteristics and current progress in related studies.

show abstract

“…Obtained easily, these cells can differentiate into any desired cells theoretically, and are applied to the study of any target cells, which are not affected by species-specific differences. The iPSCs disease models have been applied to some organ systems [21][22][23][26][27][28][29][30][31][32]. Besides, the current reprogrammed iPSCs have been widely used to study disease models and cell replacement therapy in animal experiments, which is possible to study the pathogenesis of diseases [33].…”

Section: Ivyspringmentioning

confidence: 99%

Great Expectations: Induced pluripotent stem cell technologies in neurodevelopmental impairments

Zhang

Liu

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

Somatic cells such as skin fibroblasts, umbilical cord blood, peripheral blood, urinary epithelial cells, etc., are transformed into induced pluripotent stem cells (iPSCs) by reprogramming technology, a milestone in the stem-cell research field. IPSCs are similar to embryonic stem cells (ESCs), exhibiting the potential to differentiate into various somatic cells. Still, the former avoid problems of immune rejection and medical ethics in the study of ESCs and clinical trials. Neurodevelopmental disorders are chronic developmental brain dysfunctions that affect cognition, exercise, social adaptability, behavior, etc. Due to various inherited or acquired causes, they seriously affect the physical and psychological health of infants and children. These include generalized stunting / mental disability (GDD/ID), Epilepsy, autism spectrum disease (ASD), and attention deficit hyperactivity disorder (ADHD). Most neurodevelopmental disorders are challenging to cure. Establishing a neurodevelopmental disorder system model is essential for researching and treating neurodevelopmental disorders. At this stage, the scarcity of samples is a bigger problem for studying neurological diseases based on the donor, ethics, etc. Some iPSCs are reprogrammed from somatic cells that carry disease-causing mutations. They differentiate into nerve cells by induction, which has the original characteristics of diseases. Disease-specific iPSCs are used to study the mechanism and pathogenesis of neurodevelopmental disorders. The process provided samples and the impetus for developing drugs and developing treatment plans for neurodevelopmental disorders. Here, this article mainly introduced the development of iPSCs, the currently established iPSCs disease models, and artificial organoids related to neurodevelopmental impairments. This technology will promote our understanding of neurodevelopmental impairments and bring great expectations to children with neurological disorders.

show abstract

Methods of Generation of Induced Pluripotent Stem Cells and Their Application for the Therapy of Central Nervous System Diseases

Cited by 6 publications

References 65 publications

iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams

iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams

Cell Therapy for Neurological Disorders: The Perspective of Promising Cells

Great Expectations: Induced pluripotent stem cell technologies in neurodevelopmental impairments

Contact Info

Product

Resources

About